表紙
市場調查報告書
商品編碼
721710

關鍵意見領袖 (KOL)的見解:發炎性腸道疾病 (IBD) 上「針對目標治療」方法的意義

KOL Perspectives: Implementation of the treat-to-target approach in IBD

出版日期: | 出版商: GlobalData | 英文 30 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告彙整產業關鍵意見領袖 (KOL) 的訪談調查結果,提供發炎性腸道疾病 (IBD) 的「針對目標治療 (treat-to-target)」方法的意義相關資料。

目錄

  • 摘要整理
  • 背景情況
  • 研究小組組成
  • 調查結果及其意義

附錄

目錄
Product Code: GDHC050SP

This KOL Insight briefing focuses on KOLs views of implementation of the treat-to-target approach in IBD.

The briefing includes analysis of KOL opinion on the following topic areas -

  • Perceptions of the CALM study and potential impact on Crohn's disease clinical management
  • Adoption of a T2T approach in UC
  • Impact of T2T studies on choice of therapy
  • Monitoring mucosal healing in IBD

Key Highlights

  • Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn's disease
  • T2T is used routinely in clinical practice, with an increase in a patient's disease severity used as a driver for adoption of the strategy
  • Over half the KOLs expect the CALM study to positively influence Crohn's disease management across clinical practice.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
  • In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
  • Interviews performed during December 2017
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts.

Reasons to buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "implementation of a treat-to-target (T2T) approach in IBD"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications

Appendix